Wire · opportunities
Andelyn and Its Curator® Platform Achieve First FDA-Approved Commercial Gene Therapy ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 18 September 2026 · Fusion42 review
Andelyn's Curator® platform has achieved a milestone by being part of the first FDA-approved commercial gene therapy manufacturing following the FDA's approval of Ultragenyx's FAYUVI™ for treating Sanfilippo Syndrome Type A (MPS IIIA) in the United States.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 18 Sep 2026 and 21 Sep 2026.
◆ ◆ The Wire takeaway
Andelyn's platform validation by FDA approval opens a clear path for gene therapy manufacturing ventures to scale commercial treatments in the US. You need to explore partnerships with commercial-scale platforms now that regulatory acceptance exists.
◆ Coverage
3 sources · first reported 18 Sep 2026 · latest 21 Sep 2026
◆ Related on Wire
◆ Topics